FARGO – Fargo-based Lillestol Research is signing up potential participants for a COVID-19 vaccine trial.
The two-year clinical research study “is evaluating an investigational vaccine for COVID-19 in healthy adults” ages 18 to 85, the company’s website said Wednesday, Aug. 5.
The study requires a total of five on-site visits, the website said.
Lillestol did not indicate which among the vaccines in human trials in the U.S. that it is testing.
The New York Times reported that as of Wednesday morning, Aug. 5, at least 157,300 people have died after being infected by the novel coronavirus. Nearly 4.8 million people have been confirmed to have been infected.
The North Dakota Joint Information Center reported Wednesday that the state had recorded another death tied to the coronavirus, bringing the state’s toll to 108 people.
The Minnesota Department of Health reported Wednesday that the state had recorded nine more deaths tied to the coronavirus, bringing that state’s toll to 1,629. Of those dead, 1,237 lived in long-term care or assisted living facilities.
Lillestol’s recruitment notice said that participants will be compensated for their time and will receive study-related medical care without charge. It added that there will be no overnight visits.
Lillestol Research, 4450 31st Ave S., is one of many U.S. companies involved in Operation Warp Speed.
According to the Department of Health and Human Services, Operation Warp Speed aims to deliver 300 million doses of a safe, effective vaccine for COVID-19 by January 2021. That effort is part of a broader strategy to accelerate the development, manufacturing and distribution of COVID-19 vaccines, therapeutics and diagnostics.
The World Health Organization reports that there are 26 vaccines around the world that are in clinical evaluations as of July 31. Another 139 vaccines are in preclinical evaluations.